Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

Chinese biotech firm Hangzhou Sciwind Biosciences is stepping into the high-stakes global obesity drug race, with its ...

Novo Nordisk is likely to draw investor attention on Monday after the company said it is moving forward with the oral and ...

Novo Nordisk reported mostly mild side effects from its experimental weight-loss drug CagriSema, though results upset ...

Eli Lilly & Co.’s experimental weight-loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug’s blockbuster potential in the company’s compe ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...

Novo Nordisk A/S’s next-generation obesity shot CagriSema helped patients lose weight in large studies despite only about ...

Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that ...